­
­
­
­

Inventi Rapid - Endocrinology
(Formerly Inventi Rapid/Impact: Diabetes)

Articles

  • Inventi:hec/21877/17
    SGLT2 INHIBITOR - A NEW PERSPECTIVE IN THE TREATMENT OF TYPE-II DIABETES MELLITUS
    Shaik Firoz*, Salma Shaik, Ekaja Reddy Lopinti

    Diabetes mellitus is one of the most common serious chronic metabolic disorders and one of the most leading causes of death and it is distributed worldwide. There are three main types of diabetes; those are type-I DM, type-II DM, gestational diabetes. Prevalence of Type II DM is more than Type I DM. The global prevalence rate of diabetes is increasing due to lack of effective approaches. Antidiabetic drugs like oral hypoglycemic, insulin and insulin analogues are well established and have some benefits and side effect. FDA has approved a new category of oral hypoglycemic drugs named as SGLT2 inhibitors. These are, also having similar benefits and side effect, but these have more efficacy than the other classes in monotherapy and/or combination therapy. In this review, we discussed about SGLT2 inhibitors, regarding the mechanism, benefits, side effects and their role in T2 DM.

    How to Cite this Article
    Shaik Firoz, Salma Shaik, Ekaja Reddy Lopinti. SGLT2 Inhibitor - A New Perspective in the Treatment of Type II Diabetes Mellitus. Inventi Rapid: Endocrinology, 2017(2):1-4, 2017.
    Download Full Text